34 results
Thumbnail

D1.44 - A Difficult to Treat Chronic Urticaria With Psychological Stress, High Anti-Thyroglobulin and De-labeling Hypersensitivity Reaction to Cetirizine

Thumbnail

D1.45 - Omalizumab Reduces Anaphylactic Reactions and Facilitates Food Introduction in Food-Allergic Children with Severe Asthma: A Case Report

Thumbnail

D1.48 - Challenging decisions: Feasibility and safety of multiple low-risk drug challenges in a single clinic visit during peri-operative anaphylaxis investigation

Thumbnail

D1.49 - Crossed-reactivity among Proton Pump Inhibitors in Immediate Severe Hipersensitivity Reactions

Thumbnail

D1.50 - Coconut Oil Anaphylaxis after Mucous Exposure, in a Patient with Primary Coconut Allergy

Thumbnail

D1.53 - Anaphylaxis to Beta-Lactams: The Importance of the Oral Challenge Test in Diagnosis

Thumbnail

D1.54 - Nut Allergy in the Spotlight: The Crucial Role of Oral Provocation Tests

Thumbnail

D1.55 - Assembling the Idiopathic Anaphylaxis Puzzle: Where was the secret key for Idiopathic anaphylaxis’s box?

Thumbnail

D1.46 - Allergic Reaction to Quadrivalent Meningococcal Conjugate Vaccine (MCV4): Case Report and Diagnostic Approach

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Thumbnail

D2.214 - Alpha-Amylase Inhibitors as Allergens in Wheat Flour Sensitivity